The president of the scientific corona fight committee announced the successful results of a therapeutic combination to improve pulmonary lesion in patients with corona with a faster pace.

According to the public relations and information center of the Vice-Presidency for science and technology affairs, Mostafa Ghanei, the president of the scientific corona fight committee, announced the successful results of a new therapeutic combination in patients with corona, adding: fortunately, the results of the drug have been promising due to the ability to reduce pulmonary complications, duration of hospitalization and improve treatment.

Stating that the combination of these medications reduced the length of hospital stay to 4 days compared to conventional treatments, he added: while no independent treatment has been presented for corona disease and we have not talked about a single treatment, fortunately, effective therapies for the pulmonary complications of this disease, reduction in hospital stay, and expedited discharge of patients in the country have been successful.

Three Drugs that Make the New Therapeutic Combination

The secretary of the biotechnology development headquarter, the drug is the result of a combination of three anti-inflammatory drugs for lung patients. In this regard, he mentioned: the new drug is actually the product of a combination of three drugs that are mainly anti-inflammatory. One dose of azithromycin 250 mg daily, prednisolone 25 mg daily and two doses of naproxen daily were used in these patients, which were effective.

According to Ghanei, these three drugs have no side effects and no interaction for patients with corona disease based on the instruction of the ministry of health.

Pointing out the testing of the drug on two groups of patients with corona, Ghanei marked: the first group of patients were treated according to current guidelines, but the second group used this drug, which showed a significant reduction in hospital stay and coronavirus-induced pulmonary complications.

The president of the corona fight committee expressed: the results of the reseach and the effectiveness of the drug were announced to the ministry of health, and the secretary of the national corona fight committee, and feasibility and initial agreement to initiate a treatment program are based on this combination.

Ghanei explained that the first phase of the research was performed on 28 subjects in treatment group and 31 individuals in control group, adding: the physician was not involved in the selection of patients, and some patients were under the supervision of one physician and some under the supervision of another physician, one group being used by a physician under conventional protocols and the other group using these three drugs.

The secretary of the biotechnology development headquarter pointed out that the results will be announced after the finalization of the product in the ministry of health as a new treatment instruction, adding: treatment groups will increase to 100; the findings will soon be published in an article and other countries" successful Iranian experience in this field will be shared.